Benzinga | Jun 8, 2021 04:01PM EDT

Kiniksa Reports US Patent Issued For Treatment Of Recurrent Pericarditis

Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA) ("Kiniksa"), a biopharmaceutical company with a portfolio of assets designed to modulate immunological pathways across a spectrum of diseases, today announced that the U.S Patent and Trademark Office issued a patent covering methods of using ARCALYST(r) (rilonacept) in the treatment of recurrent pericarditis.

The patent issued as U.S. Patent No. 11,026,997 and will expire on March 11, 2039. Kiniksa has exclusive rights to this patent under the ARCALYST License Agreement.

"We believe this patent continues to strengthen our proprietary position on the FDA-approved use of ARCALYST in recurrent pericarditis and provides protection that extends approximately 11 years beyond orphan drug exclusivity and into 2039," said Sanj K. Patel, Chief Executive Officer and Chairman of the Board of Kiniksa. "We continue to execute